aidsmap news story
A once-daily combination pill containing bictegravir and lenacapavir could offer a simpler alternative for people with HIV who are taking complex antiretroviral regimens, according to study results presented at CROI 2026. Gilead Sciences is testing a new single-tablet regimen consisting of 75 mg bictegravir and 50 mg lenacapavir (BIC/LEN).
The findings from ARTISTRY-1 and ARTISTRY-2 trials were presented. ARTISTRY-1 trial evaluated bictegravir plus lenacapavir as a switch option for people taking complex regimens. ARTISTRY-2 trial evaluated the BIC/LEN single-tablet regimen as a switch option for people currently taking Biktarvy.
Read the full news story here.
View all aidsmap reports from CROI 2026
SEE ALSO:
View all HIV i-Base reports from CROI 2026
View all Life4me+ reports from CROI 2026
Gilead Sciences press release:
Source : aidsmap
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Switching ART regimens common in virologically suppressed HIV
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.